Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Finding Balance: Multiobjective Optimization in Molecular Generative Modeling.

Journal of chemical information and modeling·2026
Same author

The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapy.

Biochemistry and biophysics reports·2026
Same author

Generation of WTC11 CLYBL-CAG_GCaMP8f cell line for fast and sensitive calcium tracking.

Stem cell research·2026
Same author

Pharmacological inhibition of LIF signaling reverses PD-L1-mediated immune suppression in gastric cancer.

Translational oncology·2026
Same author

Circumferential strain recovery after human cardiomyocyte transplantation in minipigs using a novel frequency-based method for myocardial tagging quantification.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2026
Same author

Correction: Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid.

Frontiers in molecular biosciences·2026

Related Experiment Video

Updated: Jun 12, 2025

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.2K

Exploring Boswellia serrata Triterpenes: A New Frontier in Leukemia Inhibitory Factor Receptor Modulation.

Claudia Finamore1, Carmen Festa1, Mattia Cammarota1

  • 1Department of Pharmacy, University of Naples "Federico II", Via D. Montesano, 49, Naples 80131, Italy.

ACS Omega
|June 9, 2025
PubMed
Summary

Boswellia serrata extract inhibits the leukemia inhibitory factor (LIF) and its receptor (LIFR) interaction, showing potential for treating liver fibrosis. Alpha-boswellic acid is identified as a key compound targeting LIFR.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.3K

Related Experiment Videos

Last Updated: Jun 12, 2025

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.2K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.3K

Area of Science:

  • Phytochemistry
  • Molecular Pharmacology
  • Hepatology

Background:

  • Boswellia serrata (Indian frankincense) possesses anti-inflammatory and anticancer properties.
  • Its therapeutic potential in hepatic fibrosis and cancer development remains largely unexplored.
  • The leukemia inhibitory factor (LIF) and its receptor (LIFR) system is implicated in hepatic fibrosis and cancer.

Purpose of the Study:

  • To investigate the effect of Boswellia serrata n-hexane extract on novel targets, specifically the LIF/LIFR interaction.
  • To identify the specific Boswellia components responsible for antagonizing the LIF/LIFR system.
  • To explore the therapeutic potential of Boswellia in hepatic fibrosis.

Main Methods:

  • Untargeted metabolomic analysis using high-resolution mass spectrometry and molecular networking.
  • Isolation and NMR spectroscopic investigation of Boswellia triterpenoid metabolites.
  • In vitro assays using LX-2 cells and computational studies to analyze molecular interactions.

Main Results:

  • The n-hexane extract of Boswellia serrata demonstrated significant antagonistic activity against the LIF/LIFR interaction.
  • Several boswellic acids and their derivatives were identified as key active metabolites.
  • Alpha-boswellic acid was confirmed as a LIFR antagonist, reducing collagen and alpha-SMA expression in LX-2 cells.
  • Computational studies revealed the crucial role of the carboxyl group in binding to the human LIFR (hLIFR) site.

Conclusions:

  • Boswellia serrata possesses compounds that can inhibit the LIF/LIFR pathway, suggesting a novel therapeutic strategy for liver fibrosis.
  • Alpha-boswellic acid is a promising candidate for developing treatments targeting hepatic fibrosis via LIFR antagonism.
  • This research opens new avenues for utilizing Boswellia-derived compounds in liver disease management.